tiprankstipranks
Trending News
More News >
Shanghai Pharmaceuticals Holding Co Class H (SHPMF)
:SHPMF
US Market

Shanghai Pharmaceuticals Holding Co (SHPMF) Income Statement

Compare
12 Followers

Shanghai Pharmaceuticals Holding Co Income Statement

Last quarter (Q2 2025), Shanghai Pharmaceuticals Holding Co's total revenue was ¥70.83B, an increase of 2.27% from the same quarter last year. In Q2, Shanghai Pharmaceuticals Holding Co's net income was ¥3.13B. See Shanghai Pharmaceuticals Holding Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 275.25B¥ 260.30B¥ 231.98B¥ 215.82B¥ 191.91B
Gross Profit
¥ 30.63B¥ 30.93B¥ 30.49B¥ 28.54B¥ 27.44B
Operating Expenses
¥ 22.49B¥ 23.26B¥ 21.71B¥ 20.62B¥ 19.30B
Depreciation and Amortization
¥ 2.42B¥ 2.19B¥ 2.22B¥ 2.14B¥ 2.14B
EBITDA
¥ 12.06B¥ 10.90B¥ 12.44B¥ 10.55B¥ 10.44B
Operating Income
¥ 8.14B¥ 7.67B¥ 9.01B¥ 8.21B¥ 7.18B
Other Income/Expenses
¥ -120.71M¥ -612.94M¥ -206.30M¥ -61.67M¥ -8.91M
Pretax Income
¥ 8.02B¥ 7.05B¥ 8.81B¥ 8.14B¥ 7.18B
Net Income
¥ 4.55B¥ 3.77B¥ 5.62B¥ 5.09B¥ 4.50B
Per Share Metrics
Basic EPS
¥ 1.23¥ 1.02¥ 1.61¥ 1.79¥ 1.58
Diluted EPS
¥ 1.23¥ 1.02¥ 1.61¥ 1.79¥ 1.58
Weighted Average Shares Outstanding
3.70B 3.70B 3.48B 2.84B 2.84B
Weighted Average Shares Outstanding (Diluted)
3.70B 3.70B 3.49B 2.85B 2.85B
Currency in CNY

Shanghai Pharmaceuticals Holding Co Earnings and Revenue History